Jonathan specialises in biotechnology investments. He currently sits on the board of Artios Pharma, Atox Bio, and STipe Therapeutics. Prior to joining Arix Bioscience, Jonathan spent five years at Touchstone Innovations (formerly Imperial Innovations), where he was a Principal in the Healthcare Ventures team. He was involved with the formation and investment in a number of early stage companies. Jonathan also worked at LifeArc, sourcing and evaluating new small molecule and antibody drug discovery projects. He has a first-class degree in biology from the University of Oxford, a PhD in Molecular Medicine from UCL, carried out postdoctoral research at the Cancer Research UK London Research Institute (now Crick Institute), and published research in various top-tier journals. Jonathan also has an MBA with distinction from Imperial College and is a Trustee of the Autism Research Trust.